News & Updates

The off-label oral solution of misoprostol proves noninferior to the licensed oral tablet for induction of labour, with no significant difference in the occurrence of vaginal delivery within 24 hours, according to a study.

The novel neurokinin-1 and -3 receptor antagonist elinzanetant appears to reduce the frequency and severity of vasomotor symptoms (VMS), as well as improve sleep and menopause-related quality of life, as shown in two pivotal phase III trials.